Zobrazeno 61 - 70
of 339
pro vyhledávání: ''
Autor:
Coleman O. Martin, Osama O. Zaidat, Italo Linfante, Nils Mueller-Kronast, Thanh N. Nguyen, Muhammad S Hussain, Alicia C. Castonguay, David S Liebeskind, Carolyn A. Cronin, Dheeraj Gandhi, John B Terry, Brenda A. Glenn, Joey English, Kevin N. Sheth, Raul G. Nogueira, Bryan Ludwig, Shyam Prabhakaran, T Malisch, Dolora Wisco, Anat Horev, Rishi Gupta, Ashis H Tayal, Tudor G Jovin, Melissa Tian, Paul F Clemmons
Publikováno v:
Cerebrovascular Diseases. 37:356-363
Background: There are multiple clinical and radiographic factors that influence outcomes after endovascular reperfusion therapy (ERT) in acute ischemic stroke (AIS). We sought to derive and validate an outcome prediction score for AIS patients underg
Publikováno v:
Cerebrovascular Diseases. 37:350-355
Background: An in situ thromboocclusion (IST) is defined as an infarct extensively involving all or most of a stenosed arterial territory, which is one major stroke mechanism related to intracranial atherosclerosis (ICAS). We focused on ISTs occurrin
Autor:
Frédéric Assal, Michel Chofflon, Magali Laidet, Patrice H. Lalive, Stéphane Armand, Gilles Allali
Publikováno v:
European Neurology, Vol. 71, No 5-6 (2014) pp. 247-251
Background: To study the 1-year evolution of quantitative dual-task gait parameters in comparison with single-task gait parameters and detailed neuropsychological assessment in patients with multiple sclerosis (MS) treated with natalizumab. Methods:
Publikováno v:
Neuroepidemiology. 43:145-149
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to be inversely related to Parkinson's disease and Alzheimer's disease, both of which may share common mechanisms with essential tremor (ET). Use of these medications has not
Publikováno v:
Cerebrovascular Diseases. 37:285-289
Background: Combination therapy with acetylsalicylic acid and dipyridamole is first-line treatment in secondary prevention of strokes. Approximately 40% of patients report headache as a side effect of dipyridamole. Dose escalation of dipyridamole red
Autor:
Fan Z. Caprio, Faiz Syed, Shyam Prabhakaran, Mark J. Alberts, Yvonne Curran, Deborah Bergman, Alexander W. Korutz, Sameer A. Ansari, Richard A. Bernstein
Publikováno v:
Cerebrovascular Diseases. 38:247-253
Background: American and European guidelines support antiplatelet agents and anticoagulants as reasonable treatments of cervical artery dissection (CAD), though randomized clinical trials are lacking. The utility of novel oral anticoagulants (NOAC),
Autor:
Conrado J. Estol, Ronald S. Freudenberger, Marco R. Di Tullio, Ralph L. Sacco, Douglas L. Mann, Min Qian, Piotr Ponikowski, Patrick M. Pullicino, John R. Teerlink, Jay P. Mohr, Stefan D. Anker, John L.P. Thompson, Dirk J. Lok, Bruce Levin, Gregory Y.H. Lip, Shunichi Homma, Susan Graham
Publikováno v:
Cerebrovascular Diseases. 38:176-181
Background and Purpose: WARCEF randomized 2,305 patients in sinus rhythm with ejection fraction (EF) ≤35% to warfarin (INR 2.0-3.5) or aspirin 325 mg. Warfarin reduced the incident ischemic stroke (IIS) hazard rate by 48% over aspirin in a secondar
Publikováno v:
European Neurology. 72:95-102
Background: Nabiximols (Sativex®), in a cannabinoid-based oromucosal spray, is an add-on therapy option for patients with moderate to severe multiple sclerosis spasticity (MSS) resistant to other medications. The study objective was to provide long-
Autor:
Joong Hyun Park, Jeong Yeon Kim, Sung Soo Lee, Won Joo Kim, Cheryl Bushnell, Sung Ik Lee, Im Seok Koh, Kyung-Yul Lee, Gyu Sik Kim, Jun Hong Lee, Jae Hyeon Park, Ok Joon Kim, Tae Jin Song, Seung Han Suk, Jong Yun Lee, Sang Won Han, Seo Hyun Kim, Hyo Suk Nam
Publikováno v:
Cerebrovascular Diseases. 38:197-203
Background: The Effect of Cilostazol in Acute Lacunar Infarction Based on Pulsatility Index of the Transcranial Doppler (ECLIPse) study showed a significant decrease in the transcranial Doppler (TCD) pulsatility index (PI) with cilostazol treatment a
Publikováno v:
Cerebrovascular Diseases. 37:181-187
Background: The mean follow-up in the clinical trials of antiplatelet drugs in the secondary prevention of ischemic atherothrombotic stroke ranges from 1 to 5.5 years. Thus, the safety and efficacy of these drugs in the very long term is not totally